Hippo signaling pathway in liver tissue homeostasis by 李玉席 et al.
?? Hereditas (Beijing)  2017? 7?, 39(7): 607?616 
www.chinagene.cn  ?  ? 
                           
????: 2017-02-26; ????: 2017-05-05 
????:? ?????????(???31625010?U1505224?J1310027)??[Supported by the National Natural Science Foundation of China (Nos. 
31625010, U1505224, J1310027)] 
????: ?????????????????????E-mail: liyuxi0608@foxmail.com 
????: ????????????????????????E-mail: dwzhou@xmu.edu.cn 
DOI: 10.16288/j.yczz.17-064 













Hippo signaling pathway in liver tissue homeostasis 
Yuxi Li, Junhong Li, Dawang Zhou 
Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen University, Xiamen 361102, China 
Abstract: Liver cancer and diseases have become the leading cause of deaths in China. Liver diseases including 
liver failure and liver cancer can be genetic or caused by a variety of factors that damage the liver, such as viruses and 
alcohol overdose. However, the underlying mechanisms that maintain liver homeostasis remain unclear. Recent stud-
ies show that the Hippo signaling pathway plays a critical role in maintaining liver tissue homeostasis. Dysregulation 
of the Hippo signaling pathway impairs liver regeneration and remarkly enhances liver overgrowth and tumorigenesis. 
In this review, we summarize recent progresses on the roles and regulation mechanisms of the Hippo signaling path-
way in liver development and diseases. 
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? 1  Hippo??????????? 
Table 1  Characterizations of the Hippo signaling pathway components 
?? ???? 
FAT(FAT atypical cadherin)  ???????????? 
FRMD6(FERM domain-containing protein 6) ????????? FERM??? 
KIBRA (kidney and brain expressed protein) ?? WW???????? 
NF2(neurofibromin 2) ????????? FERM??? 
MST1/2(mammalian Sterile 20-like kinases 1/2) Ste-20??????????? SARAH?????????? LATS1/2
? MOB1 
SAV1(protein salvador homolog 1) ?? WW? SARAH??????????? MST1/2? LATS1/2??
?? 
LATS1/2(large tumor suppressor kinases 1/2) ?? DBF-2????????????? YAP/TAZ 
MOB1A/B (Mps one binder kinase activator-like 1A/B) ?????? LATS1/2????? LATS1/2? YAP/TAZ???? 
YAP(Yes-associated protein ) ????????? TEAD??????????? 
TAZ(transcriptional coactivator with PDZ-binding motif) ????????? TEAD??????????? 
TEADs(TEA domain transcription factors) TEF?????????? YAP/TAZ????????????? 
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? 2  Hippo???????????? 
Table 2  Models of mouse with genetically modified Hippo signaling pathway 
?? ???? ???? ?? ?? 
Sav1 Sav1+/– ??????????? ?????(HCC/CC) [27] 
Sav1–/– ?????? ?? 
CAGGS-CreERT/Sav1f/f ? ?????(HCC/CC) [26] 
MMTV-Cre/Sav1f/f 
Alb-Cre/Sav1f/f ?????????????? ?????(HCC/CC) [26,27] 
Mst1/2 Mst1–/– ? ? [21,35] 
Mst2–/– ? ? 
Mst1–/–; Mst2–/– ????(E9.5) ? 
Mst1–/–; Mst2+/– ???????????MST2???? HCC??? CC??(7??)????
?(15??) 
[21] 
Mst1+/– ; Mst2–/– ????MST1???? HCC??? CC?????(15??)
CAGGS-CreERT 
Mst1–/–; Mst2f/– 
???????????????? ??? HCC??? CC??(6??) [25] 
Ad-Cre Mst1–/–; Mst2f/– ?????????????? HCC???CC?????(??? 10?) [21] 
Alb-Cre Mst1–/–; Mst2f/– ????????? ????(1??) [25] 
Alb-Cre Mst1f/f; st2f/f ??????????(1??)???
????(2??) 
HCC(4??) [26] 
Alb-Cre Mst1–/–; Mst2f/f ??????? HCC??????(3??) [21] 
Nf2 Nf2+/– ? ?????? HCC???????Nf2
????? 
[36] 
Alb-Cre/Nf2f/f ?????????????? ?????? HCC(1?) [13] 
??????????????




Yap LAP1/tTA-Yap S127A ?????????(??) ? [30] 




Ad-Cre/Yapf/f ? ? [33] 
Lats1/2 Ad-Cre Lats1 −/−; Lats2 f/f ?????????? ? [37] 
Alb-Cre Lats1f/f; Lats2f/f ????????????????
??????? 
? [18,28] 
Mob1a/b Alb-Cre Mob1af/f; Mob1b−/− ????????????????
???(3?) 
?????(HCC/CC) [29] 
Mob1a−/−; Mob1b−/− ???? ? [38] 
Mob1a+/−; Mob1b−/− ? ? 
Mob1a−/−; Mob1b+/− ?????? 50%???? 
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